Risk-Analysis Tools in Process Validation of Biopharmaceutical Drugs - The authors outline different risk-assessment tools to evaluate the crucial factors and parameters affecting product quality, pot

ADVERTISEMENT

Risk-Analysis Tools in Process Validation of Biopharmaceutical Drugs
The authors outline different risk-assessment tools to evaluate the crucial factors and parameters affecting product quality, potential failure points, and the probablity of occurrence for each unit.


BioPharm International
Volume 24, Issue 3, pp. 44-48

ABSTRACT

Process validation is required by cGMP regulations to ensure that process consistency and the ensuing product conforms to product requirements. A risk-based approach to process validation helps to identify crucial control parameters that affect product quality. The authors outline different risk-assessment tools, such as Failure-Mode-Effect Analysis (FMEA) and Fault-Tree Analysis (FTA) to evaluate the crucial factors and parameters affecting product quality, potential failure points, and the probablity of occurrence for each unit. The authors also review risk assessments performed on different cases from industrial production.

FDA defines process validation as establishing documented evidence to provide a high degree of assurance that the specific process will consistently generate a product that meets predetermined specifications and quality characteristics (1). The International Conference on Harmonization Guideline Q7A defines process validation as "the documented evidence that the process, operated within established parameters, can perform effectively reproducibly to produce an intermediate or API meeting its predetermined specifications and quality attributes" (2).

These requirements are essential as they ensure the production of a safe product that minimizes the risk to patients. Risk analysis in process validation promises to minimize process risk. Risk-assessment tools help to define the process and identify crucial areas and/or steps in that process, areas of risk and/or hazard, and critical control points (3). Performing risk assessment of scale-up and/or manufacturing process is recommended as well. The entire risk-management team should include experts from multiple disciplines to ask the following questions:
  • What can go wrong in the process?
  • How frequently can it occur?
  • What are the consequences if this process goes wrong?

The information obtained from the risk analysis will only be useful, however, if the input is appropriate. The results from the risk assessment often dictate the number of unit operation steps needed to reduce specific risks to acceptable levels.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here